Spots Global Cancer Trial Database for Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
Official Title: Efficacy and Safety of Peri-operative Sintilimab in Combination With SOX in Resectable Locally Advanced Gastric Cancer: a Multiple-center Open-label Randomized Phase II Trial.
Study ID: NCT04982939
Study Description
Brief Summary: To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Contact Details
Name: Han Liang, PhD.
Affiliation: Tianjin Medical University Cancer Institute & Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Xuewei Ding, PhD.
Affiliation: Tianjin Medical University Cancer Institute & Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
